ExploRNA Therapeutics and Wacker Biotech are strengthening our existing R&D partnership to better serve developers in the field of nucleic acid technologies and RNA/LNP-based applications.
Recognizing our complementary strengths, we have established a collaborative framework designed to facilitate seamless access to innovative solutions for our customers. This alignment integrates two critical phases of therapeutic development:
- Advanced mRNA Components: ExploRNA re-engineers mRNA components at the molecular level, offering proprietary 5′ cap analogs for co-transcriptional capping that deliver superior protein expression, reduced dsRNA contamination, and strong functional performance for therapeutic pipelines.
- Scalable Manufacturing: Wacker Biotech operates as a full-service CDMO with deep scientific and process development expertise, supporting customers with R&D grade, larger-scale and GMP-compliant RNA production.
Our primary objective is to support the biotechnology community by streamlining access to these combined capabilities. Together, we aim to help clients address critical bottlenecks in drug development and accelerate the launch and scalability of advanced mRNA programs.
